The Y-90 resin microspheres demonstrated a 98.5% best overall objective response rate, with all patients responding to the treatment.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

In her presentation at AANP 2025, Dr Haylei Lorca includes case studies of 3 patients who present with atypical psychiatric symptoms.